CoChat
Sign Up
Cited by 121

The DOI matches its Crossref record.

Transcriptional activation of p62/A170/ZIP during the formation of the aggregates: possible mechanisms and the role in Lewy body formation in Parkinson's disease

Nakaso, Kazuhiro, Yoshimoto, Yuko, Nakano, Toshiya, Takeshima, Takao, Fukuhara, Yoko, Yasui, Kenichi, Araga, Shigeru, Yanagawa, Toru, Ishii, Tetsuro, Nakashima, Kenji·2004·Brain Research
DOI 10.1016/j.brainres.2004.03.029
Open this paper in CoChat — free account

Abstract

Formation of intracellular inclusion bodies due to defects in the protein degradation machinery is associated with the pathogenesis of neurodegenerative diseases. Sequestosomal protein p62/A170/ZIP, which is an oxidative stress-related protein and a ubiquitin-binding protein, is a component protein of Lewy bodies that are observed in patients with Parkinson's disease. The association of p62 with poly-ubiquitinated proteins may be an important step in the formation of intracellular protein aggregates like Lewy bodies. To study the role of p62 in the formation of protein aggregates in PC12 cells, we monitored the intracellular localizations of p62 and ubiquitinated proteins and the levels of both components during treatment with MG132, a proteasome inhibitor. In the early stage of aggregate formation, p62 did not always co-localize with ubiquitin. In contrast, these proteins were always co-localized in later stages. After the treatment of the cells with MG132, we found that the expression level of p62 increased due to the transcriptional activation of the gene and that higher molecular sizes of p62, corresponding to mono- and di-ubiquitinated formes, were also formed. Both the transcriptional inhibitor actinomycin D and an antisense oligonucleotide of p62 inhibited the MG132-mediated increase of p62, the sequestration of ubiquitinated proteins, and the enlargement of the aggregates. Furthermore, p62-positive aggregates were observed primarily in surviving cells. Together, these…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.brainres.2004.03.029

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 33

  1. Alves-Rodrigues, 1998, Ubiquitin, cellular inclusions and their role in neurodegeneration, Trends Neurosci., 21, 516, 10.1016/S0166-2236(98)01276-4 · DOI · Paper page
  2. Andersen, 2000, What causes the build-up of ubiquitin-containing inclusions in Parkinson's disease?, Mech. Ageing Dev., 118, 15, 10.1016/S0047-6374(00)00150-0 · DOI
  3. Carrell, 1997, Conformational disease, Lancet, 350, 134, 10.1016/S0140-6736(97)02073-4 · DOI
  4. Devergne, 1996, A novel interleukin-12 p40-related protein induced by latent Epstein Barr virus infection in B lymphocytes, J. Virol., 70, 1143, 10.1128/JVI.70.2.1143-1153.1996 · DOI
  5. Dickson, 2001, α-Synuclein and Lewy body disorders, Curr. Opin. Neurol., 14, 423, 10.1097/00019052-200108000-00001 · DOI
  6. Geetha, 2002, Structure and functional properties of the ubiquitin binding protein p62, FEBS Lett., 512, 19, 10.1016/S0014-5793(02)02286-X · DOI
  7. Giasson, 2001, Parkin and the molecular pathways of Parkinson's disease, Neuron, 31, 885, 10.1016/S0896-6273(01)00439-1 · DOI
  8. Goedert, 2001, α-Synuclein and neurodegenerative diseases, Nat. Rev., Neurosci., 2, 492, 10.1038/35081564 · DOI
  9. Gong, 1999, Differential stimulation of PKC phosphorylation of potassium channels by ZIP1 and ZIP2, Science, 285, 1565, 10.1126/science.285.5433.1565 · DOI
  10. Grune, 1997, Degradation of oxidized proteins in mammalian cells, FASEB J., 11, 526, 10.1096/fasebj.11.7.9212076 · DOI
  11. Ishii, 1996, Murine peritoneal macrophages induce a novel 60-kDa protein with structural similarity to a tyrosine kinase p56lck-associated protein in response to oxidative stress, Biochem. Biophys. Res. Commun., 226, 456, 10.1006/bbrc.1996.1377 · DOI
  12. Ishii, 1997, Low micromolar levels of hydrogen peroxide and proteasome inhibitors induce the 60-kDa A170 stress protein in murine peritoneal macrophages, Biochem. Biophys. Res. Commun., 232, 33, 10.1006/bbrc.1997.6221 · DOI
  13. Ishii, 2000, Transcription factor Nrf2 coordinary regulates a group of oxidative stress-inducible genes in macrophages, J. Biol. Chem., 275, 16023, 10.1074/jbc.275.21.16023 · DOI
  14. Johnston, 1998, Aggresomes: a cellular response to misfolded proteins, J. Cell Biol., 143, 1883, 10.1083/jcb.143.7.1883 · DOI · Paper page
  15. Joung, 1996, Molecular cloning of a phosphotyrosine-independent ligand of the p56lck SH2 domain, Proc. Natl. Acad. Sci. U. S. A., 93, 5991, 10.1073/pnas.93.12.5991 · DOI
  16. Kuusisto, 2001, Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies, NeuroReport, 12, 2085, 10.1097/00001756-200107200-00009 · DOI
  17. Kuusisto, 2001, Ubiquitin-binding protein p62 expression is induced during apoptosis and proteasomal inhibition in neuronal cells, Biochem. Biophys. Res. Commun., 280, 223, 10.1006/bbrc.2000.4107 · DOI · Paper page
  18. Kuusisto, 2002, Early accumulation of p62 in neurofibrillary tangles in Alzheimer's disease: possible role in tangle formation, Neuropathol. Appl. Neurobiol., 2, 228, 10.1046/j.1365-2990.2002.00394.x · DOI
  19. Lowe, 2001, Ubiquitin and the molecular pathology of neurodegenerative diseases, Adv. Exp. Med. Biol., 487, 169, 10.1007/978-1-4615-1249-3_14 · DOI
  20. McNaught, 2001, Failure of the ubiquitin–proteasome system in Parkinson' disease, Nat. Rev., Neurosci., 2, 589, 10.1038/35086067 · DOI · Paper page
  21. Nakaso, 1999, Effects of kainate-mediated excitotoxicity on the expression of rat counterparts of A170 and MSP23 stress proteins in the brain, Brain Res. Mol. Brain Res., 69, 155, 10.1016/S0169-328X(99)00093-5 · DOI
  22. Nakaso, 2000, Oxidative stress-related proteins A170 and heme oxygenase-1 are differently induced in the rat cerebellum under kainate-mediated excitotoxicity, Neurosci. Lett., 282, 57, 10.1016/S0304-3940(00)00836-3 · DOI
  23. Puls, 1997, Interaction of protein kinase C-ξ with ZIP, a novel protein kinase C-binding protein, Proc. Natl. Acad. Sci. U. S. A., 94, 6191, 10.1073/pnas.94.12.6191 · DOI
  24. Rideout, 2001, Proteasomal inhibition leads to formation of ubiquitin/α-synuclein immunoreactive inclusions in PC12 cells, J. Neurochem., 78, 899, 10.1046/j.1471-4159.2001.00474.x · DOI
  25. Samuels, 2001, Nerve growth factor stimulates the interaction of ZIP/p62 with atypical protein kinase C and targets endosomal localization: evidence for regulation of nerve growth factor-induced differentiation, J. Cell. Biochem., 82, 452, 10.1002/jcb.1177 · DOI
  26. Shin, 1998, p62 and the sequestosome, a novel mechanism for protein metabolism, Arch. Pharm. Res., 21, 629, 10.1007/BF02976748 · DOI
  27. Stumptner, 2002, Mallory body-A disease-associated type of sequestosome, Hepatology, 35, 1053, 10.1053/jhep.2002.32674 · DOI
  28. Sudo, 2000, p62 functions as a p38 MAP kinase regulator, Biochem. Biophys. Res. Commun., 269, 521, 10.1006/bbrc.2000.2333 · DOI
  29. Terry, 2000, Do neuronal inclusions kill the cell?, J. Neural Transm., Suppl., 59, 91
  30. Tofaris, 2001, α-Synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome, FEBS Lett., 509, 22, 10.1016/S0014-5793(01)03115-5 · DOI · Paper page
  31. Vadlamudi, 1996, p62, a phosphotyrosine-independent ligand of the SH2 domain of p56lck, belongs to a new class of ubiquitin-binding proteins, J. Biol. Chem., 271, 20235, 10.1074/jbc.271.34.20235 · DOI
  32. Wooten, 2001, The atypical protein kinase C-interacting protein p62 is a scaffold for NF-κB activation by nerve growth factor, J. Biol. Chem., 276, 7709, 10.1074/jbc.C000869200 · DOI
  33. Zatloukal, 2001, p62 is a common component of cytoplasmic inclusions in protein aggregation diseases, Am. J. Pathol., 160, 255, 10.1016/S0002-9440(10)64369-6 · DOI · Paper page

Cited by

Sorted by citations

See all 121

Metadata

Authors
Nakaso, K., Yoshimoto, Y., Nakano, T., Takeshima, T., Fukuhara, Y., Yasui, K., Araga, S., Yanagawa, T., Ishii, T., & Nakashima, K.
Venue
Brain Research
Publisher
Elsevier BV
Published
2004-06
Volume
1012
Issue
1-2
Pages
42-51
ISSN
0006-8993
DOI
10.1016/j.brainres.2004.03.029
Cited by
121
References
0
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review